REPLIGEN CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 157.7 USD | -0.68% |
|
-8.08% | -12.10% |
Financials (USD)
| Sales 2024 * | 638M | Sales 2025 * | 740M | Capitalization | 8.87B |
|---|---|---|---|---|---|
| Net income 2024 * | 45M | Net income 2025 * | 88M | EV / Sales 2024 * | 13.5 x |
| Net cash position 2024 * | 284M | Net cash position 2025 * | 420M | EV / Sales 2025 * | 11.4 x |
| P/E ratio 2024 * |
272
x | P/E ratio 2025 * |
107
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.41% |
More Fundamentals
* Assessed data
More news
Latest transcript on Repligen Corporation
More recommendations
More press releases
More news
| 1 day | -3.85% | ||
| 1 week | -7.16% | ||
| Current month | -3.30% | ||
| 1 month | -7.30% | ||
| 3 months | -19.20% | ||
| 6 months | -0.89% | ||
| Current year | -11.69% |
1 week
158.27
174.36
1 month
151.82176.94
Current year
151.82211.13
1 year
110.45211.13
3 years
110.45327.32
5 years
68.39327.32
10 years
18.23327.32
| Managers | Title | Age | Since |
|---|---|---|---|
Tony Hunt
CEO | Chief Executive Officer | 60 | 14-04-30 |
Olivier Loeillot
PSD | President | 54 | 23-10-01 |
Jason Garland
DFI | Director of Finance/CFO | 50 | 23-09-24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Karen Dawes
CHM | Chairman | 72 | 05-08-31 |
| Director/Board Member | 58 | 14-06-11 | |
Martin Madaus
BRD | Director/Board Member | 64 | 23-02-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.43% | 5 M€ | -1.80% | - | |
| 1.01% | 0 M€ | 0.00% | - | |
| 0.84% | 0 M€ | 0.00% | - | |
| 0.55% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 158 | -0.46% | 181 527 |
| 24-05-23 | 158.8 | -3.85% | 430,157 |
| 24-05-22 | 165.1 | -1.06% | 456,614 |
| 24-05-21 | 166.9 | -2.84% | 358,952 |
| 24-05-20 | 171.8 | -0.09% | 319,889 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotes
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Companyâs chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Companyâs TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
158.8
USD
Average target price
204.2
USD
Spread / Average Target
+28.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.69% | 8.87B | |
| -5.31% | 181B | |
| -1.21% | 108B | |
| -5.53% | 66.57B | |
| +1.22% | 49.95B | |
| +7.03% | 43.84B | |
| +4.91% | 41.71B | |
| +21.96% | 31.59B | |
| +14.45% | 25.3B | |
| -4.81% | 23.83B |
- Stock Market
- Equities
- RGEN Stock
